Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
potassium hydroxybenzovalerate
- Development stage
- Unknown
- Lead developer
- Institute of Materia Medica, Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Potassium hydroxybenzovalerate (also known as potassium 2-(1-hydroxypentyl)benzoate or PHPB) is a water-soluble prodrug of 3-n-butylphthalide (dl-NBP), a compound originally isolated from the seeds of Apium graveolens (celery). Developed by the Institute of Materia Medica of the Chinese Academy of Medical Sciences and Yunnan Biovalley, potassium hydroxybenzovalerate is being investigated for the treatment of acute ischemic stroke and neurodegenerative diseases such as Alzheimer's disease. It acts as a modulator of the N-methyl-D-aspartate (NMDA) receptor, promoting synaptic plasticity and long-term potentiation (LTP) while protecting neurons from oxidative stress, neuroinflammation, and apoptosis. The drug has been evaluated in Phase II clinical trials in China for acute ischemic stroke.
- Other names
- potassium 2-(1-hydroxypentyl)benzoatepotassium hydroxypentylbenzoate羟戊基苯甲酸钾
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on potassium hydroxybenzovalerate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on potassium hydroxybenzovalerate.